Nosocomial pneumonia · people admitted to intensive care units
Antacids showed no clear difference in nosocomial pneumonia compared with sucralfate (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
Antacids showed no clear difference in number of participants requiring blood transfusion compared with sucralfate (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Not symptom‐free or no symptom improvement · patients with functional dyspepsia
It is very uncertain whether prokinetic changes not symptom‐free or no symptom improvement compared with placebo (very low certainty).
1 finding from 1 review
Post‐treatment symptoms scores · patients with functional dyspepsia
1 finding from 1 review
Mean difference symptoms scores · patients with functional dyspepsia
1 finding from 1 review
QoL · patients with functional dyspepsia
1 finding from 1 review
Adverse events · patients with functional dyspepsia
It is very uncertain whether prokinetic changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Not symptom‐free or no symptom improvement · patients with functional dyspepsia
It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty).
1 finding from 1 review
Post‐treatment scores · patients with functional dyspepsia
1 finding from 1 review
Mean difference symptoms scores · patients with functional dyspepsia
1 finding from 1 review
Adverse events · patients with functional dyspepsia
It is very uncertain whether other prokinetics changes adverse events compared with domperidone 10mg three times a day (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in induction of clinical remission CDAI < 150 compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 70‐point clinical response CDAI compared with placebo (low certainty).
1 finding from 1 review